Effects of folic acid and magnesium on the production of homocysteine-induced extracellular matrix metalloproteinase-2 in cultured rat vascular smooth muscle cells

Circulation Journal

Volumn 70, Issue 1, 2006, Pages 141-146

  Guo, Hangyuan ^a,b   Lee, Jong Dae ^b   Uzui, Hiroyasu ^b   Yue, Hong ^b   Wang, Junbo ^b   Toyoda, Kiyohiro ^b   Geshi, Tooru ^b   Ueda, Takanori ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

Atherosclerosis; Folic acid; Homocysteine; Magnesium; Matrix metalloproteinase; Smooth muscle cells

Indexed keywords

CELL ENZYME; FOLIC ACID; GELATIN; GELATINASE A; HOMOCYSTEINE; MAGNESIUM;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME RELEASE; ENZYME SYNTHESIS; MALE; NONHUMAN; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; AORTA; CELLS, CULTURED; CULTURE MEDIA; ENZYME INDUCTION; FOLIC ACID; HOMOCYSTEINE; MAGNESIUM SULFATE; MALE; MATRIX METALLOPROTEINASE 2; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY;

EID: 29644433170     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.141     Document Type: Article

References (38)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-809.
2. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996; 16: 28-33.
3. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125-2131.
4. Virdis A, Ghiadoni L, Salvetti G, Versari D, Taddei S, Salvett A. Hyperhomocyst(e)inemia: Is this a novel risk factor in hypertension? J Nephrol 2002; 15: 414-421.
5. Graham IM, Daly IE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 1997; 277: 1775-1781.
6. Comstock GW. Water hardness and cardiovascular diseases. Am J Epidemiol 1979; 110: 375-400.
7. Altura BT, Brust M, Bloom S, Barbour RL, Stempak JG, Altura BM. Magnesium dietary intake modulates blood lipid levels and atherogenesis. Proc Natl Acad Sci USA 1990; 87: 1840-1844.
8. Satake K, Lee JD, Shimizu H, Ueda T, Nakamura T. Relation between severity of magnesium deficiency and frequency of anginal attacks in men with variant angina. J Am Coll Cardiol 1996; 28: 897-902.
9. Guo H, Cheng J, Lee JD, Ueda T, Shan J, Wang J. Relationship between the degree of intracellular magnesium deficiency and the frequency of chest pain in women with variant angina. Herz 2004; 29: 299-303.
10. Guo H, Lee JD, Guo M, Lu Y, Tang F, Ueda T. Status of intracellular and extracellular magnesium concentration in patients with cardiac syndrome X. Acta Cardiol 2005; 60: 259-263.
11. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1998; 136: 480-490.
12. Uzui H, Lee JD, Shimizu H, Tsutani H, Ueda T. The role of proteintyrosine phosphorylation and gelatinase production in the migration and proliferation of smooth muscle cells. Atherosclerosis 2000; 149: 51-59.
13. Tsukada T, Tippens D, Gordon D, Ross R, Gown AM. HHF35, a muscle-actin-specific monoclonal antibody. I: Immunocytochemical and biochemical characterization. Am J Pathol 1987; 126: 51-60.
14. Tyagi SC, Meyer L, Schmaltz RA, Reddy HK, Voelker DJ. Proteinases and restenosis in the human coronary artery: Extracellular matrix production exceeds the expression of proteolytic activity. Atherosclerosis 1995; 116: 43-57.
15. Pickering G, Ford CM, Tang B, Chow LH. Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells: Evidence for repressed collagen production and activated degradative capacity. Arterioscler Thromb Vasc Biol 1997; 17: 475-482.
16. Foda HD, George S, Rollo E, Drews M, Conner C, Cao J, et al. Regulation of gelatinases in human airway smooth muscle cells: Mechanism of progelatinase A activation. Am J Physiol 1999; 277: L174-L182.
17. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996; 148: 121-128.
18. Selhub J. Homocysteine metabolism. Ann Rev Nutr 1999; 19: 217-246.
19. Guo H, Lee JD, Ueda T, Shan J, Wang J. Plasma homocysteine levels in patients with early coronary artery stenosis and high risk factors. Jpn Heart J 2003; 44: 865-871.
20. Gerritsen T, Waisman HA. Homocysteinuria, an error in the metabolism of methionine. Pediatrics 1964; 33: 413-420.
21. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
22. Lee HY, Chae IH, Kim HS, Park YB, Choi YS, Lee YW, et al. differential effects of homocysteine on porcine endothelial and vascular smooth muscle cells. J Cardiovasc Pharmacol 2002; 39: 643-651.
23. Bescond A, Augier T, Chareyre C, Garcon D, Hornebeck W, Charpiot P. Influence of homocysteine on matrix metalloproteinase-2: Activation and activity. Biochem Biophys Res Commun 1999; 263: 498-503.
24. Shibata M, Ueshima K, Harada M, Nakamura M, Hiramori K, Endo S, et al. Effect of magnesium sulfate pretreatment and significance of matrix metalloproteinases-1 and interleukin-6 levels in coronary reperfusion therapy for patients with acute myocardial infarction. Angiology 1999; 50: 573-582.
25. Woo KS, Chook P, Chan LL, Cheung AS, Fung WH, Qiao M, et al. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. Am J Med 2002; 112: 535-539.
26. Guo H, Lee JD, Xing Y, Cheng J, Ueda T, Toyoda K, et al. Changes of homocysteine levels and arterial endothelial function in patients with high risk of coronary artery disease after 6-month folic acid supplementation. Acta Cardiol 2004; 59: 503-506.
27. Guo H, Lee JD, Ueda T, Cheng J, Shan J, Wang J. Hyperhomocysteinaemia and folic acid supplementation in patients with high risk of coronary artery disease. Indian J Med Res 2004; 119: 33-37.
28. Willems FF, Aengevaeren WR, Boers GH, Blom HJ, Verheugt FW. Coronary endothelial function in hyperhomocysteinemia: Improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 766-772.
29. Gottsater A, Forsblad J, Mattiasson I, Lindgarde F. Decreasing plasma endothelin-1 and unchanged plasma neopterin during folate supplementation in hyperhomocysteinemia. Int Angiol 2002; 21: 158-164.
30. Holven KB, Aukrust P, Holm T, Ose L, Nenseter MS. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vasc Biol 2002; 22: 699-703.
31. Stanger O. Physiology of folic acid in health and disease. Curr Drug Metab 2002; 3: 211-223.
32. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 2002; 15: 157-163.
33. Narin F, Narin N, Akcakus M, Ustdal M, Karakucuk I, Halici C. The effect of folic acid, vitamin B6 and vitamin B12 on the homocysteine levels in rabbits fed by methionine-enriched diets. Tohoku J Exp Med 2002; 198: 99-105.
34. Hagar HH. Folic acid and vitamin B12 supplementation attenuates isoprenaline-induced myocardial infarction in experimental hyperhomocysteinemic rats. Pharmacol Res 2002; 46: 213-219.
35. 2+ versus organic calcium channel blockers on myogenic tone and agonist-induced responsiveness of blood vessels. Can J Physiol Pharmacol 1987; 65: 729-745.
36. Yue H, Lee JD, Shimizu H, Uzui H, Mitsuke Y, Ueda T. Effects of magnesium on the production of extracellular matrix metalloproteinases in cultured rat vascular smooth muscle cells. Atherosclerosis 2003; 166: 271-277.
37. 2+ entry in vascular smooth muscle cells. Circulation 1997; 95: 2567-2572.
38. i, and atherogenesis and stroke. Neurosci Lett 1999; 274: 83-86.